Latest Hotspot

Halia Therapeutics Revels $30M Series C Funding for Inflammation Treatments

11 February 2024
3 min read

Halia Therapeutics, an emerging leader in the biopharmaceutical field focused on the development of new small molecule drugs to tackle inflammatory diseases, has successfully finalized its Series C funding round amounting to $30 million. The investment round was spearheaded by Todd Pedersen, and saw sustained contributions from prior backers.

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The capital raised through this funding round is earmarked for the progression of Halia's principal compound, HT-6184. This compound is a first-of-its-kind, NLRP3/NEK7 inflammasome inhibitor, known for its selectivity and effectiveness when administered orally and is currently undergoing Phase II clinical evaluations. Halia Therapeutics is at the forefront of a new Phase IIa study in India, targeting therapy for individuals diagnosed with lower-risk myelodysplastic syndromes.

Lower-risk MDS refers to a spectrum of hematological malignancies characterized by defective and morphologically atypical bone marrow cells, identified as dysplastic. Moreover, the company is intent on initiating Phase II U.S. trials for HT-6184 to explore its efficacy in controlling inflammatory pain following medical procedures, and embarking on a Phase I study in those affected by Alzheimer's disease.

The investment will further facilitate pre-INVESTIGATIONAL New Drug activities for Halia's nascent projects, which focus on the development of Leucine-rich repeat kinase 2 (LRRK2) antagonists. These are being researched as potential treatments for neurodegenerative disorders like Parkinson's and Alzheimer's disease. Resources are also allocated to bolster both the clinical and regulatory teams, substantially strengthening the company’s capacity to drive its portfolio's international progression.

Todd Pedersen reflects on the innovation of Halia Therapeutics, stating, "With Halia's pioneering strategy in honing in on the NLP3 inflammasome, we anticipate groundbreaking progress in the treatment of diverse inflammatory conditions, blood disorders, and various cancers." He further underscores the invaluable contributions of the company, highlighting its expertise and commitment to patient-centric development as critical in transforming the management of chronic inflammation for affected individuals.

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of February 8, 2024, there are 1 investigational drugs for the NLRP3/NEK7 target, including 2indications, 1R&D institutions involved, with related clinical trials reaching 3, and as many as 72 patents.

HT-6184 shows promise as a potential treatment for myelodysplastic syndromes and inflammation. Its targeting of NEK7 and NLRP3 highlights its potential to modulate disease pathways and provide therapeutic benefits. With its current status in Phase 2, further clinical trials will be necessary to evaluate its safety and efficacy in larger patient populations. If successful, HT-6184 could address unmet medical needs in the field of hemic and lymphatic diseases, as well as other diseases associated with inflammation.

图形用户界面, 文本, 网站

描述已自动生成

Maximize Your Synapse Use: Your Guide to Searching Meclizine
Drug Insights
2 min read
Maximize Your Synapse Use: Your Guide to Searching Meclizine
11 February 2024
Meclizine is a small molecule drug that acts as an antagonist of histamine (H1) receptors.
Read →
Bio-Thera Solutions Initiates Phase 1B/2A Study for BAT6026 Monoclonal Antibody in Eczema Treatment
Latest Hotspot
3 min read
Bio-Thera Solutions Initiates Phase 1B/2A Study for BAT6026 Monoclonal Antibody in Eczema Treatment
9 February 2024
Bio-Thera Solutions has launched an early-stage clinical study, specifically Phase 1B/2A, for its novel monoclonal antibody, BAT6026, aimed at OX40 for treating individuals experiencing moderate to intense eczema.
Read →
Master Rosuvastatin Search on Synapse
Drug Insights
2 min read
Master Rosuvastatin Search on Synapse
9 February 2024
Rosuvastatin, sold as Ezallor and Crestor, is a small molecule inhibiting liver cholesterol synthesis by blocking HMG-CoA reductase enzyme.
Read →
New Insights: Vabysmo Effectively Treats Retinal Swelling in Retinal Vein Occlusion Patients
Latest Hotspot
3 min read
New Insights: Vabysmo Effectively Treats Retinal Swelling in Retinal Vein Occlusion Patients
9 February 2024
Recent findings on Genentech's drug Vabysmo indicate persistent efficacy in reducing retinal swelling and enhancing eyesight for those with Retinal Vein Occlusion.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.